Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE: 605177)
Health Care · Pharmaceuticals · CN
CN¥20.73
+11.63% today · -1.1% 1Y
Zhejiang East Asia Pharmaceutical Co., Ltd. (SHSE: 605177) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $347.07M and employs 1,514 people.
Over the last twelve months the share price has lost 1.1%, trading between 13.71 and 24.70.
Tweenvest scores Zhejiang East Asia Pharmaceutical Co., Ltd. across four factors: quality 63/100, value 54/100, growth 20/100. Its strongest factor is quality.
605177 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $347.07M
- Revenue (TTM)
- $146.99M
- P/E
- —
- EPS
- -0.97
- Dividend yield
- —
- Beta (5Y)
- 0.80
- 52-week high
- CN¥24.70
- 52-week low
- CN¥13.71
- Avg volume (3M)
- —
- Shares outstanding
- 112.55M
- Employees
- 1,514
- Next earnings
- —
About Zhejiang East Asia Pharmaceutical Co., Ltd.
Founded in 1992, Zhejiang East Asia Pharmaceutical Co., Ltd. operates in the manufacture and supply of active pharmaceutical ingredients (APIs), tablets, granules, and capsules. The company's principal office is situated in Taizhou, China.
- Founded
- 1998
- Listed since
- Nov 25, 2020
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,239.69 | -1.25% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.54 | +0.48% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $149.86 | -1.76% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.10 | -1.73% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.32 | -1.70% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.88 | -0.68% |
Figures last refreshed Aug 18, 2026.